Walvax Biotechnology News

Walvax Biotechnology: Peking Guofeng (Shanghai) Law Firm's Legal Opinion Regarding the First Extraordinary Shareholders' Meeting of the Company in 2024.

Jul 26 12:00 ET

Walvax Biotechnology: Announcement of the resolution of the first extraordinary Shareholders' Meeting in 2024.

Jul 26 12:00 ET

Walvax Biotechnology: Announcement Regarding the Change of the Purpose of Repurchased Shares and the Cancellation and Reduction of the Company's Registered Capital and Notification to Creditors.

Jul 26 12:00 ET

Walvax Biotechnology: Announcement Regarding the Appointment of Company's CFO.

Jul 22 12:00 ET

Walvax Biotechnology: Notice regarding the convening of the first extraordinary shareholders' meeting in 2024.

Jul 22 12:00 ET

Walvax Biotechnology: Announcement Regarding the Revision of the Company's Articles of Association

Jul 9 12:00 ET

Walvax Biotechnology: Notice of the First Extraordinary Shareholders' Meeting in 2024

Jul 9 12:00 ET

Walvax Biotechnology: Announcement regarding the resignation of some directors and senior management personnel at the company.

Jul 9 12:00 ET

Walvax Biotechnology: Announcement regarding the appointment of the company's president and the election of directors.

Jul 9 12:00 ET

Walvax Biotechnology: Announcement Regarding the Adjustment of Company Organizational Structure

Jun 25 12:00 ET

Walvax Biotechnology: Announcement on termination of clinical trial of new coronavirus mRNA vaccine in cooperation with Suzhou Abogen Biosciences Co., Ltd.

Jun 25 12:00 ET

Walvax Biotechnology: Announcement regarding termination of the technical development cooperation for COVID-19 mRNA vaccine and shingles mRNA vaccine with Suzhou Abogen Biosciences Co., Ltd. and signing of termination agreement.

Jun 25 12:00 ET

Walvax Biotechnology: Announcement Regarding the Resignation of the Company's Human Resources Director.

Jun 21 12:00 ET

Walvax Biotechnology: Announcement on termination of clinical trials for recombinant novel coronavirus vaccines (CHO cells) and recombinant novel coronavirus mutant strain vaccines (CHO cells)

Jun 17 12:00 ET

Watson Biotech: Announcement on Changing the Use of Repurchased Shares and Cancelling and Reducing the Company's Registered Capital

Apr 25 12:00 ET

Watson Biotech: Announcement on holding an online briefing on the results for the first quarter of 2024

Apr 24 12:00 ET

Watson Biotech: Prompt Announcement for the Disclosure of the 2024 First Quarter Report

Apr 24 12:00 ET

Watson Biotech: Announcement on the termination of clinical trials of the recombinant novel coronavirus vaccine (chimpanzee adenovirus vector)

Apr 24 12:00 ET

Watson Biotech: Announcement on Changing the Use of Repurchased Shares and Cancelling and Reducing the Company's Registered Capital and Notifying Creditors

Apr 22 07:55 ET

Watson Biotech: Legal Opinion of Beijing Guofeng Law Firm on the Company's 2023 Annual General Meeting of Shareholders

Apr 19 12:00 ET